A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O’Rourke(University of Pennsylvania), MacLean P. Nasrallah(University of Pennsylvania), Arati Desai(University of Pennsylvania), J. Joseph Melenhorst(University of Pennsylvania), Keith G. Mansfield(Novartis (United States)), Jennifer J.D. Morrissette(Computational Diagnostics (United States)), Maria Martinez‐Lage(University of Pennsylvania), Steven Brem(University of Pennsylvania), Eileen Maloney(University of Pennsylvania), Angela Shen(Novartis (United States)), Randi Isaacs(Novartis (United States)), Suyash Mohan(University of Pennsylvania), Gabriela Plesa(University of Pennsylvania), Simon F. Lacey(University of Pennsylvania), Jean‐Marc Navenot(University of Pennsylvania), Zhaohui Zheng(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), Hideho Okada(University of California, San Francisco), Carl H. June(University of Pennsylvania), Jennifer L. Brogdon(Novartis (United States)), Marcela V. Maus(Massachusetts General Hospital)
Cited by 1,760Open Access
Abstract
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.
Related Papers
No related papers found
Powered by citation graph analysis